Bellerophon Therapeutics, Inc. (BLPH)
| Market Cap | 146.79K |
| Revenue (ttm) | 5.64M |
| Net Income (ttm) | -9.25M |
| Shares Out | 12.23M |
| EPS (ttm) | -0.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Dec 19, 2024 |
| Volume | 7,027 |
| Open | 0.0120 |
| Previous Close | 0.0161 |
| Day's Range | 0.0120 - 0.0126 |
| 52-Week Range | 0.0100 - 0.1000 |
| Beta | 0.70 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 31, 2025 |
About Bellerophon Therapeutics
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonar... [Read more]
Financial Performance
Financial StatementsNews
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Bellerphon Therapeutics stock plunges toward record selloff after lung disease treatment performs worse than placebo in late-stage trial
Shares of Bellerophon Therapeutics Inc. BLPH, -83.00% plummeted 83% toward a record one-day decline, after the biotherapeutics company said its lung-disease treatment failed to meet its primary endpoi...
Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
WARREN, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatment...
Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results
WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments...
Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease
WARREN, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments...
Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results
WARREN, N.J., March 31, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatmen...
Bellerophon Therapeutics Announces $5 Million Registered Direct Offering
WARREN, N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatmen...
Bellerophon Therapeutics Receives IND Clearance from China NMPA to Conduct Phase 3 Clinical Trial in China for INOpulse® in Fibrotic Interstitial Lung Disease
China NPMA accepts the use of Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint China NPMA accepts the use of Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint
Bellerophon Therapeutics Announces Completion of Enrollment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease
Enrollment concludes earlier than anticipated; pivotal top-line data now expected mid-2023 Enrollment concludes earlier than anticipated; pivotal top-line data now expected mid-2023
Bellerophon Therapeutics Announces License Agreement for the Commercialization of INOpulse® in Greater China with Baylor BioSciences
Bellerophon to receive a license payment of $6 million, as well as royalties on net sales in Greater China Bellerophon to receive a license payment of $6 million, as well as royalties on net sales in ...
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results
Ongoing INOpulse® REBUILD Phase 3 trial enrollment completion expected in the first quarter of 2023, with pivotal top-line data readout anticipated in the third quarter of 2023 Ongoing INOpulse® REBUI...
Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
WARREN, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatmen...
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results
WARREN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatment...
Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference
WARREN, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments...
Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results
WARREN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments...
Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results
WARREN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatmen...
Bellerophon to Present at the H.C. Wainwright BioConnect 2022 Conference
WARREN, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatment...
Bellerophon Stock Surges After Positive Data From Sarcoidosis-Associated Pulmonary Hypertension Trial
Bellerophon Therapeutics Inc (NASDAQ: BLPH) shares are trading higher after topline data from Phase 2 study (PULSE-PHPF-002) evaluating the acute hemodynamic benefit of INOpulse via right heart cathet...
Bellerophon Reports Positive Top-Line Data from Phase 2 Acute Dose Escalation Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Sarcoidosis
Phase 2 results provide clinically meaningful reduction in pulmonary vascular resistance; Company intends to design multi-dose Phase 2b trial
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2021 Financial Results
WARREN, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatment...
Bellerophon to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
WARREN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatmen...
Why Entera Bio, Orphazyme, Bellerophon Are Moving Today
Entera Bio Ltd. (NASDAQ: ENTX), Orphazyme A/S (NASDAQ: ORPH) and Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) are among the biggest biopharma movers Wednesday.
Bellerophon to Present at the Jefferies Virtual Healthcare Conference
WARREN, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments...
Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors
Dr. Amin Has Served as an Independent Director Since 2015 and Succeeds Jonathan Peacock Following Mr. Peacock's Retirement from the Company's Board Dr. Amin Has Served as an Independent Director Since...
Bellerophon Provides Clinical Program Update and Reports First Quarter 2021 Financial Results
WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments...